US2016355469A1PendingUtilityA1
Anticonvulsant compounds
Assignee: OWEN-BARRY PHARMACEUTICALS INCPriority: Jun 5, 2015Filed: Jun 6, 2016Published: Dec 8, 2016
Est. expiryJun 5, 2035(~8.9 yrs left)· nominal 20-yr term from priority
A61P 43/00C07C 255/31A61P 25/04C07C 2601/16C07C 2601/02A61P 25/08C07C 2101/02C07C 2101/14
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application relates to compounds and methods for reducing the severity of convulsant activity, or epileptic seizures.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound represented by the following formula (I):
wherein,
R=H, CH 3 , C 2 to C 6 (linear or branched), cC 3 H 5 , cC 5 H 9 , cC 6 H 11 , CH=CH 2 , or CH 2 Ar,
R 1 =R 2 =H or CH 3 ,
R 3 =R 4 =H or CH 3 ,
R 5 =H, CH 3 , OCH 3 , OCH 2 Ar, Cl, or Br, and
R 6 =H or CH 3 .
2 . The compound of claim 1 , wherein R=H, CH 3 , C 2 to C 6 (linear or branched), cC 3 H 5 , cC 5 H 9 , or cC 6 H 11 .
3 . The compound of claim 2 , wherein R 5 =H or CH 3 .
4 . The compound of claim 3 , wherein R=H, CH 3 , or C 2 to C 6 (linear or branched).
5 . The compound of claim 4 , wherein R=H or CH 3 .
6 . The compound of claim 1 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
7 . The compound of claim 1 , wherein the compound represented by the formula (I) is 2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile.
8 . The compound of claim 1 , wherein the compound represented by the formula (I) is 3-methyl-2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile.
9 . The compound of claim 1 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
10 . The compound of claim 1 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
11 . The compound of claim 1 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
12 . The compound of claim 1 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
13 . A pharmaceutical composition for reducing the severity of convulsant activity, comprising a compound represented by the following formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient:
wherein,
R=H, CH 3 , C 2 to C 6 (linear or branched), cC 3 H 5 , cC 5 H 9 , cC 6 H 11 , CH=CH 2 , or CH 2 Ar,
R 1 =R 2 =H or CH 3 ,
R 3 =R 4 =H or CH 3 ,
R 5 =H, CH 3 , OCH 3 , OCH 2 Ar, Cl, or Br, and
R 6 =H or CH 3 .
14 . The pharmaceutical composition of claim 13 , wherein R=H, CH 3 , C 2 to C 6 (linear or branched), cC 3 H 5 , cC 5 H 9 , or cC 6 H 11 .
15 . The pharmaceutical composition of claim 14 , wherein R 5 =H or CH 3 .
16 . The pharmaceutical composition of claim 15 , wherein R=H, CH 3 , or C 2 to C 6 (linear or branched).
17 . The pharmaceutical composition of claim 16 , wherein R=H or CH 3 .
18 . The pharmaceutical composition of claim 13 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
19 . The pharmaceutical composition of claim 13 , wherein the compound represented by the formula (I) is 2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile.
20 . The pharmaceutical composition of claim 13 , wherein the compound represented by the formula (I) is 3-methyl-2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile.
21 . The pharmaceutical composition of claim 13 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
22 . The pharmaceutical composition of claim 13 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
23 . The pharmaceutical composition of claim 13 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
24 . The pharmaceutical composition of claim 13 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
25 . A method for reducing the severity of convulsant activity, comprising administering to a subject a therapeutically effective amount of a compound represented by the following formula (I):
wherein,
R=H, CH 3 , C 2 to C 6 (linear or branched), cC 3 H 5 , cC 5 H 9 , cC 6 H 11 , CH=CH 2 , or CH 2 Ar,
R 1 =R 2 =H or CH 3 ,
R 3 =R 4 =H or CH 3 ,
R 5 =H, CH 3 , OCH 3 , OCH 2 Ar, Cl, or Br, and
R 6 =H or CH 3 .
26 . The method of claim 25 , wherein R=H, CH 3 , C 2 to C 6 (linear or branched), cC 3 H 5 , cC 5 H 9 , or cC 6 H 11 .
27 . The method of claim 26 , wherein R 5 =H or CH 3 .
28 . The method of claim 27 , wherein R=H, CH 3 , or C 2 to C 6 (linear or branched).
29 . The method of claim 28 , wherein R=H or CH 3 .
30 . The method of claim 25 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
31 . The method of claim 25 , wherein the compound represented by the formula (I) is 2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile.
32 . The method of claim 25 , wherein the compound represented by the formula (I) is 3-methyl-2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile.
33 . The method of claim 25 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
34 . The method of claim 25 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
35 . The method of claim 25 , wherein the compound represented by the formula (I) is a compound represented by the following formula:
36 . The method of claim 25 , wherein the compound represented by the formula (I) is a compound represented by the following formula:Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.